Follow the Evidence From Baseline to Exposure

Begin with the observation, before asking a crop to explain it. Zwart and colleagues studied 20 astronauts. In the five crew members who developed ophthalmic change, homocysteine, cystathionine, 2-methylcitric acid, and methylmalonic acid were 25 to 45 percent higher than in the 15 who did not. The differences were present before launch and persisted during and after flight (P < 0.001) (Zwart et al. 2012).

That result points toward susceptibility present before launch. It does not establish that food, a nutrient dose, or a supplement can prevent or mitigate spaceflight-associated neuro-ocular syndrome, or SANS. For Gastronaut and NASA, the responsible research question is narrower: can a specified, traceable nutritional exposure change a prespecified biochemical or ocular endpoint?

ORCA can support that inquiry by preserving what was grown, what a participant consumed, and when the exposure occurred. NASA-led investigators would define the biochemical and ocular endpoints. The research product is the connection among those records, not a predetermined clinical outcome.

Follow the signal across the evidence

The observation sits within a bounded synthesis of 388 analysable studies drawn from 3,375 unique records. One hundred concern human spaceflight, and 163 concern human ground analogs. Full-text retrieval did not run, so the counts describe indexed abstracts and cannot establish field-wide absences.

The next analysis broadened the human evidence. Among 49 astronauts, MTRR and SHMT1 variants were associated with visual outcomes. In one block-regression example, genetic information trended toward improving the refractive-change model at P = 0.10. B-vitamin status improved it at P < 0.001 (Zwart et al. 2016).

A European ground-analog cohort then supplied another view. It included 24 participants, 22 of whom provided genetic samples. The same MTRR A66G and SHMT1 C1420T variants were associated with greater retinal-thickness change. Preflight optic cup volume combined with genotype predicted the change better than either factor alone (Zwart et al. 2024).

The pattern across these studies concerns baseline biochemistry, genotype, anatomy, and later ocular change. Confidence is moderate that one-carbon metabolism and baseline anatomy contribute to differences in SANS susceptibility. Confidence remains low that a particular food, crop, nutrient dose, or supplement prevents or mitigates SANS. Association, interpretation, and intervention therefore remain distinct claims.

Let the flight case change the study design

The flight case adds practical information. B-vitamin supplementation began after retinal thickening had developed. Cabin carbon dioxide fell during the intervention, so the authors could not separate the two effects. Gastrointestinal discomfort ended supplementation after 16 days. The case informs feasibility and monitoring rather than an efficacy estimate (Gastronaut).

An investigator would carry each feature into the next protocol. Timing must show that an exposure preceded the outcome. Environmental conditions must remain visible when they change. Tolerance must be monitored because it determines whether a planned dose is delivered. A useful study can preserve what happened under each condition even when the clinical hypothesis remains open.

This leads back to the narrower question supported by the evidence: does a specified exposure change a prespecified biochemical or ocular endpoint? The answer must be collected for that purpose rather than inferred from an earlier association.

Reconstruct the exposure before interpreting the response

Gastronaut is developing ORCA as a ground-stage cultivation system at approximately TRL 3 to 4, with no flight or lunar operating history. Its proposed role in this domain is research support. Every study would require its own qualification. Crop efficacy, nutrient consistency, food safety, crew outcomes, ocular effects, and system economics would each require evidence designed for that claim.

The exposure record starts with provenance. Seed lot, cultivation condition, light, carbon dioxide, temperature, humidity, irrigation, harvest age, and storage interval remain attached to the sampled edible material. A composition result can then be interpreted in the conditions that produced it.

Laboratory analysis of sampled tissue is paired with the weight of food offered, food consumed, and residual waste. The consumed portion, rather than the harvested crop in the abstract, becomes the exposure entered into the human-research record.

Controlled variation provides the comparison. Researchers can define a production condition intended to alter a nutrient or food property, verify the resulting composition, and retain a matched comparator. Plant response remains distinguishable from participant response.

A common time base completes the reconstruction. Production, harvest, consumption, blood sampling, imaging, cabin conditions, medication use, symptoms, and adherence share timestamps. The record can then show whether a preflight susceptibility marker, an inflight exposure, and a postflight image belong to the same research question.

Ask the platform to prove a research service

ORCA is research infrastructure rather than a SANS treatment. A proposed study could establish whether the system produces material with a specified composition and whether participants consume a specified amount under controlled conditions. NASA clinical investigators would determine ocular and biochemical endpoints, safety provisions, eligibility criteria, and statistical design.

The platform’s research value would be measured through traceability, repeatability, data completeness, fault handling, labour, resource use, and reproduction of a declared exposure. A clinical study may support a health inference when its endpoint, comparator, design, and uncertainty justify the claim. The inference remains bounded by the study conditions. It does not confer regulatory approval or establish claims beyond those conditions.

This division of responsibility serves both institutions. NASA can examine a modifiable hypothesis without a predetermined answer. Gastronaut can reach a capability milestone tied to the quality of its research service rather than a promised clinical outcome.

Gastronaut proposes a ground-study design session with NASA specialists in nutrition, ocular health, human research, food safety, and data. The group would select one bounded question, define the exposure and comparator, and agree on the chain from crop production to ocular measurement before testing begins.

An investigator returning to the work later should be able to see why every finding was made, reproduce the exposure, challenge the interpretation, and improve the design. Preserving the conditions behind each result allows the evidence to mature one claim at a time. It also leaves future teams, and the crews their work may serve, a sound place from which to continue.

References

Gastronaut. Ocular Health and Spaceflight-Associated Neuro-ocular Syndrome: Evidence Synthesis. Evidence version 22 Aug. 2026. Research synthesis.

Zwart, Sara R., et al. “Vision Changes After Spaceflight Are Related to Alterations in Folate- and Vitamin B-12-Dependent One-Carbon Metabolism.” The Journal of Nutrition, 2012. https://doi.org/10.3945/jn.111.154245.

Zwart, Sara R., et al. “Genotype, B-Vitamin Status, and Androgens Affect Spaceflight-Induced Ophthalmic Changes.” FASEB Journal, 2016. https://doi.org/10.1096/fj.15-278457.

Zwart, Sara R., et al. “Optic Disc Edema During Strict 6-Degree Head-Down Tilt Bed Rest Is Related to One-Carbon Metabolism Pathway Genetics and Optic Cup Volume.” Frontiers in Ophthalmology, 2024. https://doi.org/10.3389/fopht.2023.1279831.